BIOHEART-B(02185): IBERIS RDN system completes market access and first commercial surgery in Switzerland.

BIOHEART-B (02185) announced that recently, the Iberis multi-pole renal artery radiofrequency ablation system (Iberis RDN system) developed by its subsidiary Shanghai Antong Medical Technology Co., Ltd. (Antong) has completed market access and the first commercial operation in Switzerland. The surgery was performed by the University Hospital Basel with no reported complications or adverse events. This case was supported by the joint efforts of BIOHEART-B and Antong. Antong and BIOHEART-B have established a strategic partnership for the commercialization of the Iberis RDN system, with cooperation covering multiple regions including but not limited to EU countries, the Asia-Pacific region, and the Latin America (LATAM) region. As of the date of this announcement, the Iberis RDN system is the only renal nerve blockade (RDN) product approved for use using transradial artery (TRA) and transfemoral artery (TFA) approaches globally. TRA makes RDN safer, more effective, and more cost-effective. The company's ultimate goal is to provide outpatient RDN surgery for patients worldwide. Antong obtained the CE mark for the Iberis RDN system in Europe in 2016.